Prana Biotechnology Limited researches and develops therapeutic drugs for the treatment of Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidates include PBT434 that is in Phase I clinical trial for the treatment for Parkinson's disease and other movement disorders; and PBT2, which has completed four Phase I studies and a Phase IIa clinical trial for patients with Alzheimer's disease. It also completed the IMAGINE Phase II biomarker imaging trial in Alzheimer's disease; and a open label IMAGINE Extension study and the Reach2HD Phase IIa trial in Huntington disease. The company was founded in 1997 and is based in Melbourne, Australia.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone61-3-9349-4906
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$150,000.00
Profitability
Miscellaneous
Employees14
OptionableNot Optionable
Prana Biotechnology (NASDAQ:PRAN) Frequently Asked Questions
What is Prana Biotechnology's stock symbol?
Prana Biotechnology trades on the NASDAQ under the ticker symbol "PRAN."
Has Prana Biotechnology been receiving favorable news coverage?
Headlines about PRAN stock have trended positive this week, according to InfoTrie. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Prana Biotechnology earned a coverage optimism score of 2.3 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the stock's share price in the next several days.
Who are some of Prana Biotechnology's key competitors?
Some companies that are related to Prana Biotechnology include NewLink Genetics (NLNK), Oramed Pharmaceuticals (ORMP), Vaccinex (VCNX), Eyenovia (EYEN), CTI BioPharma (CTIC), VIVUS (VVUS), Scpharmaceuticals (SCPH), Arcturus Therapeutics (ARCT), Evoke Pharma (EVOK), Aravive (ARAV), Clearside Biomedical (CLSD), Vascular Biogenics (VBLT), Bellerophon Therapeutics (BLPH), Vistagen Therapeutics (VTGN) and DiaMedica Therapeutics (DMCAF).
Who are Prana Biotechnology's key executives?
Prana Biotechnology's management team includes the folowing people:
- Mr. Geoffrey Paul Kempler, Co-Founder, Exec. Chairman, CEO & MD (Age 64)
- Ms. Kathryn Andrews, Chief Financial Officer (Age 52)
- Dr. David A. Stamler, Chief Medical Officer, Sr. VP of Clinical Devel. and Member of R&D Advisory Board (Age 58)
- Prof. Rudolph Emile Tanzi, Chief Scientific Advisor and Member of R&D Advisory Board
- Dr. Steven D. Targum M.D., Chief Medical Advisor
How do I buy shares of Prana Biotechnology?
Shares of PRAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Prana Biotechnology's stock price today?
One share of PRAN stock can currently be purchased for approximately $1.6150.
How big of a company is Prana Biotechnology?
Prana Biotechnology has a market capitalization of $14.37 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-6,400,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Prana Biotechnology employs 14 workers across the globe.
What is Prana Biotechnology's official website?
How can I contact Prana Biotechnology?
Prana Biotechnology's mailing address is Level 3 460 Bourke Street, Melbourne C3, 3000. The biotechnology company can be reached via phone at 61-3-9349-4906 or via email at [email protected]
MarketBeat Community Rating for Prana Biotechnology (NASDAQ PRAN)
MarketBeat's community ratings are surveys of what our community members think about Prana Biotechnology and other stocks. Vote "Outperform" if you believe PRAN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRAN will underperform the S&P 500 over the long term. You may vote once every thirty days.
